These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 1968739)

  • 1. [Noninvasive evaluation of partial beta adrenergic agonist properties of xamoterol in cardiac insufficiency].
    Richaud M; Lechat P; Komajda M; Landault C; Fournier P; Fraysse JB; Grosgogeat Y
    Arch Mal Coeur Vaiss; 1990 Feb; 83(2):247-52. PubMed ID: 1968739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of xamoterol on resting and exercise haemodynamics in patients with chronic heart failure.
    Virk SJ; Davies MK
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):15S-22S. PubMed ID: 2572250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hemodynamic and humoral changes following intravenous administration of xamoterol in patients with heart failure and coronary heart disease].
    Erlemeier HH; Kupper W; Bleifeld W
    Z Kardiol; 1990 Feb; 79(2):126-33. PubMed ID: 1969685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Assessment of chronotropic effect and arrhythmogenesis on beta 1-partial agonist (Xamoterol) in chronic heart failure].
    Fukuda K; Handa S; Ogawa S; Nakamura Y; Kawamura Y
    Kokyu To Junkan; 1988 Nov; 36(11):1227-33. PubMed ID: 2907820
    [No Abstract]   [Full Text] [Related]  

  • 5. Xamoterol in patients with dilated cardiomyopathy: an increase in beta-receptors in lymphocytes.
    Watanabe K; Hirokawa Y; Shibata A
    J Cardiol; 1988 Dec; 18(4):1015-25. PubMed ID: 2908309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The acute effects of intravenous xamoterol ('Corwin', I.C.I. 118, 587) on resting and exercise haemodynamics in patients with mild to moderate heart failure.
    Virk SJ; Anfilogoff NH; Lawson N; Sadler AM; Smith SJ; Nuttall A; Murray RG; Littler WA; Davies MK
    Eur Heart J; 1989 Mar; 10(3):227-34. PubMed ID: 2565233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of adrenergic beta receptor partial agonists in left ventricular failure of ischemic origin. Value of xamoterol (ICI 118,587, Corwin)].
    Rousseau MF; Cheron P; Nannan M; Vincent MF; Lavenne F; Pouleur H
    Ann Med Interne (Paris); 1985; 136(3):247-50. PubMed ID: 2862823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of beta 1-partial agonist(ICI 118-587) on plasma catecholamines level and hemodynamics during exercise in congestive heart failure].
    Sato H; Matsuyama T; Ozaki H; Fukushima M; Matsumoto M
    Kokyu To Junkan; 1984 Nov; 32(11):1159-62. PubMed ID: 6151727
    [No Abstract]   [Full Text] [Related]  

  • 9. Partial agonist activity of bucindolol is dependent on the activation state of the human beta1-adrenergic receptor.
    Maack C; Böhm M; Vlaskin L; Dabew E; Lorenz K; Schäfers HJ; Lohse MJ; Engelhardt S
    Circulation; 2003 Jul; 108(3):348-53. PubMed ID: 12847069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The value of xamoterol in moderate ischemic cardiac insufficiency].
    Rousseau MF; Cheron P; Vincent MF; Pouleur H; Lavenne F
    Ann Cardiol Angeiol (Paris); 1984; 33(4):215-8. PubMed ID: 6147115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of beta-1 adrenoceptor agonist and antagonist potency and selectivity of cicloprolol, xamoterol and pindolol.
    Hicks PE; Cavero I; Manoury P; Lefevre-Borg F; Langer SZ
    J Pharmacol Exp Ther; 1987 Sep; 242(3):1025-34. PubMed ID: 2888869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of tolerance development after long-term administration of the partial beta-adrenoceptor agonist xamoterol.
    Erlemeier HH; Kupper W; Bleifeld W
    Cardiology; 1990; 77(1):30-9. PubMed ID: 1972349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of dobutamine on renal sympathetic activity in human heart failure.
    Al-Hesayen A; Parker JD
    J Cardiovasc Pharmacol; 2008 May; 51(5):434-6. PubMed ID: 18398381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of clinical experience with xamoterol. Effects on exercise capacity and symptoms in heart failure.
    Marlow HF
    Circulation; 1990 Feb; 81(2 Suppl):III93-8. PubMed ID: 1967561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Acute effect of the cardioselective beta-1-partial agonist, Corwin, on ventricular function and myocardial oxygen consumption in patients with dilated cardiomyopathy].
    Amende I; Simon R; Hood WP; Lichtlen PR
    Z Kardiol; 1986 May; 75(5):291-5. PubMed ID: 2874668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose dobutamine responsiveness in idiopathic dilated cardiomyopathy: relation to exercise capacity and clinical outcome.
    Scrutinio D; Napoli V; Passantino A; Ricci A; Lagioia R; Rizzon P
    Eur Heart J; 2000 Jun; 21(11):927-34. PubMed ID: 10806017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological analysis of the cardiac actions of xamoterol, a beta adrenoceptor antagonist with partial agonistic activity, in guinea pig heart: evidence for involvement of adenylate cyclase system in its cardiac stimulant actions.
    Hattori Y; Sakuma I; Nakao Y; Kanno M
    J Pharmacol Exp Ther; 1987 Sep; 242(3):1077-85. PubMed ID: 2888870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of xamoterol in moderate cardiac insufficiency].
    Kayanakis JG; Larouchi L; Doat P; Grenet B; Fauvel JM; Bounhoure JP
    Presse Med; 1989 Apr; 18(13):667-70. PubMed ID: 2566161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of the partial beta 1-agonist xamoterol on heart rate and ventricular arrhythmias in patients with mild to moderate heart failure.
    Virk SJ; Anfilogoff NH; Lawson N; Qiang F; Murray RG; Littler WA; Davies MK
    Eur Heart J; 1990 Oct; 11(10):876-84. PubMed ID: 1979946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Xamoterol, a beta1-adrenoceptor partial agonist: a new approach to heart failure. Proceedings of the 1st International Heart Failure. Interlaken, 1988.
    Barnett DB; Breckenridge A
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):1S-91S. PubMed ID: 2572249
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.